Chardan Capital analyst Keay Nakae reiterated a Buy rating on Arrowhead Pharmaceuticals (ARWR – Research Report) yesterday and set a price ...

Arrowhead Pharmaceuticals, Inc. ( NASDAQ:ARWR ) shareholders should be happy to see the share price up 11% in the ...

Charles Schwab Investment Management Inc. increased its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – ...

Arrowhead (ARWR) announced interim results from a Phase 1/2a clinical study of ARO-CFB, the company’s investigational RNA interference, or ...

Fmr LLC cut its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 10.9% in the third quarter, ...

ARO-DUX4, which is being developed as a treatment for facioscapulohumeral muscular dystrophy type 1 and is currently in a Phase 1/2 clinical trial. ARO-DM1, which is being developed as a treatment ...

Arrowhead Pharmaceuticals Inc (ARWR) stock saw a decline, ending the day at $23.11 which represents a decrease of $-2.96 or -11.35% from the prior close of $26.07. The stock opened at $26.15 and ...

On Friday, Arrowhead Pharmaceuticals Inc (ARWR) stock saw a decline, ending the day at $26.03 which represents a decrease of $-0.12 or -0.46% from the prior close of $26.15. The stock opened at $26.15 ...

U.S. stocks on Wednesday slipped, as investors digested a slight acceleration in the Federal Reserve's favorite inflation ...

Arrowhead Pharmaceuticals' stock rallied 17% due to significant pipeline developments and strategic partnerships. Learn more ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from a Phase 1/2a clinical study of ARO-CFB, the company’s investigatio ...